For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
AlphaLISA features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
IRAK4 (Human Interleukin 1 Receptor Associated Kinase 4) is a serine/threonine protein kinase involved in signaling innate immune response. IRAK4 is recruited by MD88 through TLR signaling, where it phosphorylates IRAK1 and ultimately results in NF-kappa-B nuclear translocation and activation. IRAK4 supports signaling from T-cell receptors. IRAK4 contains domain structures which are similar to those of IRAK1, IRAK2, IRAKM and Pelle. IRAK4 is unique compared to IRAK1, IRAK2 and IRAKM in that it functions upstream of the other IRAKs but is more similar to Pelle in this trait. Animals deficient in IRAK-4 are more susceptible to viruses and bacteria but completely resistant to LPS challenge.
檢測目標 | IRAK4 |
---|---|
檢測目標類 | Protein |
自動化兼容 | Yes |
檢測方法 | Alpha |
產品品牌名稱 | AlphaLISA |
運輸條件 | 藍冰 |
治療領域 | Inflammation |
產品尺寸 | 500 Assay Points |
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more da ...
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...